The voltage-gated potassium channel Kv1.3 is a well-established target for treatment of autoimmune diseases. ShK peptide from a sea anemone is one of the most potent blockers of Kv1.3 but its application as a therapeutic agent for autoimmune diseases is limited by its lack of selectivity against other Kv channels, in particular Kv1.1. Accurate models of Kv1.x-ShK complexes suggest that specific charge mutations on ShK could considerably enhance its specificity for Kv1.3. Here we evaluate the K18A mutation on ShK, and calculate the change in binding free energy associated with this mutation using the path-independent free energy perturbation and thermodynamic integration methods, with a novel implementation that avoids convergence problems. To check the accuracy of the results, the binding free energy differences were also determined from path-dependent potential of mean force calculations. The two methods yield consistent results for the K18A mutation in ShK and predict a 2 kcal/mol gain in Kv1.3/Kv1.1 selectivity free energy relative to wild-type peptide. Functional assays confirm the predicted selectivity gain for ShK[K18A] and suggest that it will be a valuable lead in the development of therapeutics for autoimmune diseases.
Introduction
High-affinity binding to the target protein is a key criterion in the search for drug leads, and several methods, from highthroughput screening to computational docking, have been used for this purpose. The selectivity of a drug lead for a given target is also important as high affinity for an unintended target could lead to unacceptable side effects. In principle, experimental or computational screening methods developed for lead searching can be used to address the selectivity problem, although the complexity of proteins compared to lead ligands makes such brute force methods less likely to be successful. Methods based on structure-based drug design provide a promising alternative for solving selectivity problems, as we illustrate in this study, which also identifies a potent analog of ShK peptide that is selective for the voltage-gated potassium channel Kv1.3.
Kv1.3 is a well-established target for the treatment of autoimmune diseases mediated by effector memory T EM lymphocytes, such as multiple sclerosis and rheumatoid arthritis [1, 2] . ShK peptide, from the sea anemone Stichodactyla helianthus [3] [4] [5] , is a potent blocker of the Kv1.3 channel with an IC 50 of around 10 pM [6] , and thus an excellent lead for development of an immunomodulatory drug [7] . However, ShK also blocks other Kv channels with high affinity, in particular Kv1.1 (IC 50 = 16 pM) [6] . This lack of specificity for Kv1.3 is an impediment for the use of ShK as a therapeutic agent, and considerable effort has gone into developing ShK analogs with improved selectivity for Kv1.3 over Kv1.1 and other potassium channels [5, 7] . Several analogs with the desired selectivity have been developed, e.g. ShK-Dap22 [6] , ShK-F6CA [8] , ShK-186 [9] , and ShK-192 [10] , but all of them contain non-natural amino acids and/or adducts, and, in the case of ShK-186, the phosphorylated Tyr residue is susceptible to hydrolysis. For this reason, it is desirable to develop selective ShK analogs for Kv1.3 containing only natural amino acids.
An essential first step in searching for selective analogs using structure-based drug design methods is to construct accurate models of the relevant protein-ligand complexes. This has been achieved recently for Kv1.x-ShK complexes using docking and molecular dynamics (MD) simulations [11, 12] . The validity of the complex models was established by comparing the predicted binding modes with alanine scanning mutagenesis data [13, 14] , and showing that the binding free energies of ShK obtained from the potential of mean force (PMF) calculations reproduce the experimental values within chemical accuracy [11] . Comparison of the binding modes in the Kv1.1-ShK and Kv1.3-ShK complexes reveals that the side chain of K18 in ShK is strongly coupled to a glutamate side chain in Kv1.1 via electrostatic interactions but it does not exhibit any interactions with the Kv1.3 residues [11] . Thus, mutation of this residue in ShK to alanine could lead to a substantial selectivity gain for Kv1.3 over Kv1. 1. Here we perform free energy simulations to calculate the change in the binding free energy of the Kv1.1-ShK and Kv1.3-ShK complexes associated with the K18A mutation. Two independent methods are used to check the veracity of the calculations. First we perform free energy perturbation (FEP) and thermodynamic integration (TI) calculations where ShK in the binding site is transformed to ShK[K18A] while the reverse transformation is carried out in the bulk for ShK[K18A], which gives directly the change in the binding free energy due to the mutation. We avoid convergence problems by using uncharged side chains as intermediate states. Convergence of the results was checked using the TI method, which also demonstrates the robustness of the calculations. Secondly, the PMFs for the dissociation of ShK[K18A] from Kv1.x are constructed from umbrella sampling MD simulations, from which the relative and absolute binding free energies of ShK[K18A] are determined. The change in the binding free energy is obtained by subtracting the relative binding free energy of the mutant from that of wild-type peptide [11] . The FEP and TI methods are computationally much cheaper but their reliability is not very well established for charge mutations. Thus, one of our aims was to demonstrate that the free energy change due to a charge mutation can be calculated accurately using the FEP and TI methods. The predictions of the free energy calculations were confirmed by measuring the binding constants of ShK[K18A] for Kv1.1 and Kv1.3 by patch-clamp electrophysiology.
Materials and Methods

Ethics statement
All procedures involving vertebrate animals were conducted after approval by the Institutional Animal Care and Use Committee at Baylor College of Medicine. Baylor College of Medicine follows the requirements of the Guide for the Care and Use of Laboratory Animals (National Research Council, 8th edition). Female Lewis rats were purchased from Taconic (Germantown, NY, USA) and housed in autoclaved setup with food and water ad libitum in an Association for Assessment and Accreditation of Laboratory Animal Care International (ALAAAC)-approved facility. Every effort was made to minimize animal discomfort and to keep the number of animals used to a minimum. Rats were euthanized by deep isoflurane anesthesia (slow breathing and lack of reactivity to toe pinching), followed by cardiac puncture. Death was ensured by decapitation.
Peptide synthesis
The synthesis of the peptide has been described before [14] . Briefly, Fmoc-amino acid derivatives were obtained from Bachem A.G. (CH-4416 Bubendorf, Switzerland). Solid-phase assembly was initiated with an Fmoc-Cys(Trt)-2-chlorotrityl resin to minimize potential racemization of the C-terminal Cys residue. Automated stepwise assembly was carried out entirely on an ABI-431A peptide synthesizer (Applied Biosystems, Foster City, CA). ShK[K18A] was solubilized, oxidized, and purified by reverse phase-high pressure liquid chromatography using the method described previously [6, 13] , and high pressure liquid chromatography-pure fractions were pooled and lyophilized. The structure and purity of the peptides were confirmed by reverse phase-high pressure liquid chromatography, amino acid analysis, and electrospray ionization-mass spectroscopy analysis. Samples were weighed and adjusted to account for peptide content before bioassay. The purity and mass were determined using LC and ESI-MS analyses (Figures S1 and S2 in File S1). Figure S5 in File S1).
NMR spectroscopy and data analysis
Cells
Mouse L929 fibroblasts stably expressing mKv1.1, mKv1.3, hKv1.5 channels [15] were gifts from Dr. K. George Chandy (University of California, Irvine). Human embryonic kidney 293 cells stably expressing hKv11.1 (hERG) were a gift from Dr. Craig January (University of Wisconsin, Madison). CCR7
2 Ova-GFP T EM cells (gift from Dr. Flügel, Munich, Germany) were derived from Lewis rats and react to ovalbumin [16] ; they were maintained in culture through alternating rounds of antigendependent stimulation and of expansion in a cytokine-rich medium [17, 18] . As antigen-presenting cells for T EM cell stimulation, we used irradiated (30 Gy) thymocytes harvested from humanely euthanized Lewis rats [17] . Histopaque-1077 gradients (Sigma-Aldrich) were used to isolate splenocytes from the same Lewis rats [9, 19] .
Electrophysiology
Electrophysiology experiments were conducted in the whole-cell configuration of the patch-clamp technique on a Port-a-Patch (Nanion Technologies, North Brunswick, NJ) connected to an EPC10-USB amplifier (HEKA Instruments, Bellmore, NY) [18, 20] . A holding potential of 280 mV was used for all recordings. Pipette resistances averaged 2.0 MV and series resistance compensation of 80% was employed when currents exceeded 2 nA. Kv1.3 currents were elicited by repeated 200-ms pulses from 280 mV to 40 mV, applied at intervals of 30 or 60 s.
Kv1.3 currents were recorded in normal Ringer solution with a Ca 2+ -free pipette solution containing (in mM): 145 KF, 10 HEPES, 10 EGTA, 2 MgCl2, pH 7.2, 300 mOsm. IC 50 -values were determined by fitting the Hill equation to the reduction of area under the current curve measured at 40 mV. Kv1.1 and Kv1.5 currents were recorded with 200-ms depolarizing pulses to 40 mV applied every 10 sec. HERG (Kv11.1) currents were recorded with a 2-step pulse from 280 mV first to 20 mV for 2 sec and then to 250 mV for 2 sec and the reduction of both peak and tail current by the drug was determined.
T Lymphocyte proliferation assays
The T EM cells were used after 4 days of IL-2-dependent expansion. The splenic T cells were used immediately after collection from Lewis rats. Cells were seeded in flat-bottom 96-well plates in 200 mL of culture medium supplemented with 1% homologous rat serum. ShK or ShK[K18A] were added to the cells 30 min before the antigen or mitogen. T EM cells were stimulated with 10 mg/ml ovalbumin in the presence of irradiated thymocytes as antigen-presenting cells and splenocytes were 
Delayed type hypersensitivity
Lewis rats were immunized against ovalbumin [17] and a week later challenged in the pinna of one ear with ovalbumin or saline [17, 21] . They received a subcutaneous injection of 100 mg/kg ShK[K18A] at time of challenge and ear thickness was determined 24 h later as a measure of inflammation [9, 17, 18] .
Modeling of Kv1.x-ShK[K18A] complexes
The solution structure of ShK was obtained from the Protein Data Bank (PDB ID, 1ROO) [22] . Homology models of Kv1.1 and Kv1.3 were taken from previous work [11] . The structure of ShK[K18A] was generated from that of ShK using the VMD plugin, Mutator [23] . Two-dimensional homonuclear NMR spectroscopy was used to confirm that the solution structure of this analog was essentially identical with that of ShK [22, 24] (Figures S3, S4, S5 in File S1). The Kv1.x-ShK[K18A] complex models were generated via docking and refinement with MD following the same protocols used for Kv1.x-ShK complexes [11] . Briefly, the structure ShK[K18A] was equilibrated in bulk MD simulations for 5 ns, and ten frames were chosen for use in docking calculations. The initial Kv1.x-ShK[K18A] complexes were obtained using HADDOCK [25] . For both Kv1.1 and Kv1.3, the top ten poses with the highest scores were found to be very similar, and the one with the highest score was chosen for refinement with MD. Each complex structure was embedded in a lipid bilayer consisting of 125 POPC molecules and solvated with 10,525 water molecules and 0.1 M KCl. After the correct water and lipid densities were obtained with pressure coupling, the protein-toxin complex was gradually relaxed in 5-ns MD simulations. The equilibrated system was run for another 5 ns for analysis of the complex structure, where convergence of the channel protein and toxin peptide was monitored using the RMSD of the backbone atoms. MD simulations were performed using the NAMD program [26] with the CHARMM27 force field [27] , which includes the CMAP correction [28] . An NpT ensemble was used with the temperature and pressure maintained at 300 K and 1 atm, respectively, via Langevin coupling with damping coefficients of 5 ps 21 and 10 ps 21 . Periodic boundary conditions were employed together with particle-mesh Ewald algorithm to compute the long-range electrostatic interactions. Lennard-Jones (LJ) interactions were switched off within a distance of 10-12 Å , and the list of non-bonded interactions was truncated at 13.5 Å . A time step of 2 fs was used, and the trajectory data were written at 1 ps intervals.
FEP and TI Calculations
The free energy change due to a mutation is most efficiently calculated using the alchemical transformation methods such as FEP and TI [29] , where the side chain of an amino acid is gradually transformed into another side chain and the free energy change is determined from the free energies of the end-points. This also applies to a protein-ligand complex, provided the binding mode is not altered by the mutation, which is the case for the K18A mutation in the Kv1.x-ShK complexes considered here. To avoid the problems posed by the change in the charge state, we implement the thermodynamic cycle in Figure 1 . Accordingly, while the K18A mutation was applied to ShK in the binding site, the reverse transformation was applied to the toxin in the bulk simultaneously and in the same system, which ensures that the net charge in the system did not change during the calculations. To deal with convergence issues, we separated the Coulomb and LJ interactions and performed the K18A mutation in three stages as depicted in Figure 1 . First, the K18 side chain on the bound ShK was discharged, while the reverse process was performed on ShK in the bulk with an uncharged K18 side chain. Secondly, the uncharged K18 side chain on the bound ShK was transformed to an uncharged A18 side chain, while the reverse was performed on the bulk ShK. Finally, the A18 side chain in the binding site was 
The average atom-atom distances obtained from 5 ns MD simulations are listed in column 3 for the wild-type complexes and in column 6 for the mutant complexes (in units of Å ). Subscripts refer to the side chain atoms and the monomer identity in K + channels is given in parentheses. doi:10.1371/journal.pone.0078712.t001 charged, while the corresponding side chain in the bulk was discharged (note that the Ala side chain is neutral overall but has small partial charges on C and H atoms). The change in the binding free energy due to the K18A mutation can, thus, be expressed as The first and last terms on the right hand side give the Coulomb contributions to the free energy change and the middle term gives the LJ contribution. Each term is calculated using the FEP and/or TI methods. In both methods, one introduces a hybrid Hamiltonian, H(l)~(1{l)H 0 zlH 1 , where H 0 represents the Hamiltonian for the initial state and H 1 for the final state. In the FEP method, the interval [0,1] is divided into n subintervals with [l i , i = 1,…,n -1], and for each subinterval the free energy difference is calculated from the ensemble average,
The free energy difference between the initial and final states is obtained from the sum, DG~X i DG i . Provided DG i #2 kT for each window [27] , the FEP sum should converge with reasonable sampling. For charge mutations, satisfaction of this condition would require over 130 windows if uniform subintervals were used. Using exponentially spaced subintervals instead halves the required number of windows to 66 (the l values are provided in File S1). Each window was equilibrated for 80 ps followed by a 120-ps production run. These were found to be optimal times after several tests with different times. We also performed the backward calculation to check for hysteresis effects. The system was equilibrated for 5 ns after the forward transformation before starting the backward transformation. For the LJ part, we used 30 equally-spaced windows at the end points, i.e., for l between 0-0.3 and 0.7-1, and 20 equally-spaced windows in between. Using 20-ps equilibration and 30-ps production run for each window was found to be adequate. In order to improve convergence and prevent instabilities, we used a soft-core LJ potential with a shift coefficient of 7.0 [30] .
In the TI method, the ensemble average of the derivative, LH(l)=Ll, was obtained at several l values, and the free energy difference was calculated from the integral, DGð 1 0 SLH(l)=LlT l dl: The TI method was especially advantageous for charge interactions because Gaussian quadrature allows evaluation of the integral using a small number of windows, which can be sampled for longer times to check convergence of the results. A seven-point quadrature was found to be adequate in previous applications of the TI method [31] , which was also adopted here (the l values are provided in File S1). The initial TI windows were taken from the nearest FEP window. Each window was typically equilibrated for 1 ns and sampled for 1 ns. The TI method has not been used in the calculation of the LJ interactions because it offers no advantages over FEP (it requires as many windows due to the unsuitability of Gaussian quadrature and takes longer time), and good results have already been obtained using FEP. 
PMF Calculations
PMF provides the most reliable method for calculation of the absolute binding free energies of charged peptides, which can be directly compared to the experimental values. Unlike the FEP and TI methods, which give the free energy difference between two states, PMF provides a continuous free energy profile between the initial and final states. This makes PMF computationally more expensive than the FEP and TI methods. Nevertheless, it is very useful for testing of alternative methods. The PMFs for unbinding of ShK from Kv1.x are available from earlier work [11] , and those for ShK[K18A] were constructed here using the umbrella sampling MD simulations employing the protocols developed in earlier work [11, 32] . Briefly, umbrella windows are generated at 0.5 Å intervals along the channel axis using steered MD simulations with k = 30 kcal/mol/Å 2 and v = 5 Å /ns. After each pulling step, the toxin was equilibrated for 0.4 ns with the same restraining force to relax the effect of steering on the environment. The reaction coordinate was measured from the center of mass of the channel protein to the center of mass of the toxin along the z axis, which was aligned with the channel axis. A minimum of 5% overlap between the sampling of neighboring windows was required for an accurate construction of the PMF [32] . When the overlap was below this limit, e.g. due to a sharp rise in the PMF, an extra window was included between the two windows. The same umbrella force constant (30 kcal/mol/Å 2 ) was used in all windows, which was found to be optimal for this size toxin [32] . The PMF was constructed from the reaction coordinates of ShK[K18A] collected during the umbrella sampling simulations via the weighted histogram analysis method [33] . Simulations were continued until the convergence of each PMF is assured. The binding constant was determined from the integral of the PMF, W(z), along the reaction coordinate, and the absolute binding energy from the log of the binding constant: (Figure 2) . In both complex structures, there is a very good overlap between the backbones of the mutant and wild-type ShK, indicating that the K18A mutation causes minimal perturbation of the binding mode. This observation is made more quantitative in Table 1 , which compares the average interatomic distances between the strongly interacting residues in the mutant and wild-type complexes. All the contact pairs are seen to be preserved after the mutation in both complexes, and the changes in the pair distances are well within the fluctuations for all the strongly coupled pairs (distance , 4 Å ).
Results and Discussion
Free energy changes from FEP and TI calculations
Provided the binding mode is preserved, the most straightforward way to calculate the binding free energy change due to a mutation on a ligand is to use the FEP and/or TI methods. To facilitate convergence, we adopted a staged approach, as described in Figure 1 . We used both methods for the charging/discharging steps where convergence issues are critical for the long-range Coulomb interactions. Evidence for the convergence of the FEP and TI calculations for charging/discharging of Lys side chain is provided in Figure 3 . Mutation of the uncharged Lys to Ala involves short-range LJ interactions, where convergence is not an issue provided the windows at the end points are chosen at small intervals. Because the TI method offers no advantages, we have performed three independent FEP calculations for the LJ step. Convergence of the FEP calculations for the LJ step is demonstrated in Figure 3B . Detailed results of the FEP and TI calculations showing the individual contributions from the three steps in both forward and backward directions for the Kv1.1 and Kv1.3 channels are presented in Table 2 . We note that there is negligible hysteresis between the forward and backward calculations in all cases, and the FEP and TI calculations yield consistent results for the charging/discharging steps. As expected, the main contribution to the free energy difference comes from The FEP and TI results are taken from Table 2 , and the PMF results are obtained from Table 3 the charging/discharging of the Lys side chain, while the charging/discharging of the Ala side chain makes a negligible contribution.
Free energy changes from PMF calculations PMF calculations were then performed to check the accuracy of the FEP and TI calculations. The binding constants and absolute binding free energies obtained from PMFs also allow a direct comparison with the experimental values. The PMFs for the unbinding of ShK from Kv1.1 and Kv1.3 were constructed in our earlier work [11] . Here we repeat these PMF calculations for ShK[K18A] using the same protocols. Convergence studies of the PMFs from block data analysis ( Figures S6 and S7 in File S1) show that the PMF in the Kv1.3-ShK[K18A] system converges relatively quickly, just as in the case of the Kv1.3-ShK system [11] , and the final PMFs for ShK and ShK[K18A] are very similar (Figure 4) . Convergence of the PMF in the Kv1.1-ShK [K18A] system is delayed somewhat (Figures S6 and S7 in File S1), which can be traced to the slow equilibration of the E353-R29 side chain interactions. As expected, abolishing a charge interaction in the Kv1.1-ShK[K18A] system leads to a shallower PMF compared with that for Kv1.1-ShK. An interesting feature of the ShK[K18A] PMF is the absence of the shoulder region observed in the ShK PMF, which is caused by the long-range Coulomb interactions, in particular by the E353-R29 pair [11] . E353-R29 pair due to rotation of the toxin and its subsequent dissociation ( Figure S8 in File S1). Absolute binding free energies obtained from the integration of the PMFs (eq 2) are compared to the experimental values in Table 3 . In all cases, the calculated binding free energies agree with the experimental values within the chemical accuracy of 1 kcal/mol, which provides strong support for the accuracy of the complex models.
Selectivity free energies
The results of the binding free energy differences obtained using various approaches are summarized in Table 4 together with the experimental values. The FEP and TI results are in good agreement with those of the PMF, which indicates that the former methods can be used reliably in calculation of the free energy differences associated with mutation of amino acids. The TI method gives slightly better results compared with FEP for charge interactions, presumably because of longer sampling of windows. The crucial question of the selectivity free energy gain for Kv1.3/Kv1.1 associated with the K18A mutation is addressed in the last column of 
Experimental validation of modeling results
In order to validate the modeling results by experimentation, we used the well-established technique of whole-cell patch-clamp. Using this technique, mouse fibroblasts stably expressing either Kv1.1 or Kv1.3 channels were patch-clamped to measure total potassium currents through these channels. Figure 5A ) [20] . ShK also inhibited Kv1.1 channels with a high affinity (IC 50 = 25.662.8 pM) ( Figure 5B ). In contrast, ShK[K18A] exhibited a 124-fold selectivity for Kv1.3 over Kv1.1 channels (IC 50 on Kv1.1 = 4,9006200 pM).
A potential concern when developing potassium channel blockers is off-target toxic effects on cardiac channels. We therefore used the whole-cell patch-clamp assay to determine the effects of ShK[K18A] on the two cardiac potassium channels Kv1.5 and Kv11.1 (hERG). ShK[K18A] had no effects on either cardiac potassium channels when tested at concentrations of up to 100 nM (results not shown).
Since selective Kv1.3 channel blockers are known to preferentially inhibit the proliferation of CCR7 2 T EM lymphocyte with little to no effect on the proliferation of CCR7 + naïve and T CM lymphocytes, we next tested the effects of ShK and ShK[K18A] on the proliferation of rat T lymphocytes. Both peptides displayed a marked preferential inhibition of the proliferation of T EM lymphocytes ( Figure 5C ) with little effect on naïve/T CM cells ( Figure 5D ). These results suggest that ShK[K18A] is selective for Kv1.3 over KCa3.1 channels as naïve/T CM cells rely on KCa3.1 channels for their proliferation [1] .
Finally, we used an active DTH reaction to ovalbumin to determine the in vivo ability of ShK[K18A] to inhibit a T EM lymphocyte-mediated inflammatory reaction. ShK[K18A] reduced this active DTH reaction by ca 52% (Figure 5E ), exhibiting similar activity to ShK-186 and ShK-192 in this model [10] .
These results demonstrate that ShK[K18A] is bioavailable and can inhibit T EM cells both in vitro and in vivo, making it a compound of considerable interest for immunomodulation and treatment of T EM -mediated diseases.
Conclusions
Increasing the selectivity of a drug lead for a specified target is a design problem that in principle could be greatly facilitated using computational methods. Here we have described the case of ShK peptide, which binds with high affinity to the Kv1.3 channel and is a potential drug lead for the treatment of autoimmune diseases. We have analyzed the K18A mutation in ShK, which was suggested by accurate models of Kv1.x-ShK complexes, and shown via free energy calculations, to produce a 2 kcal/mol gain in selectivity free energy for Kv1.3/Kv1.1. Experimental confirmation of this result increases confidence in the ability of the free energy methods, in particular computationally cheaper FEP and TI methods, to predict the effects of mutations accurately. Moreover, the potency of ShK[K18A] against Kv1.3, its selectivity for this channel over Kv1.1, its preferential inhibition of T EM cells over naïve and T CM cells, its ability to significantly reduce a DTH reaction, and the fact that it is composed entirely of protein amino acids, make it an attractive candidate for further evaluation as a therapeutic for autoimmune diseases.
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